{"public_id":"cl_c0cbba752a00713606631f7c27497675","status":"active","superseded_by_public_id":null,"corpus_id":24762552,"text":"Adjusted hazard ratio for cancer incidence with pravastatin use was 0.78, with a 95% confidence interval of 0.18 to 3.46.","confidence":0.96,"paper":{"corpus_id":24762552,"title":"Pravastatin Use and the Five-year Incidence of Cancer in Coronary Heart Disease Patients: from the Prevention of Coronary Sclerosis Study","url":"https://sah.borca.ai/papers/24762552"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.96,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_03dafabe2df58591d708f92f7f9800ee","name":"cancer incidence","description":"Occurrence of new cancer cases during the five-year follow-up.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_03dafabe2df58591d708f92f7f9800ee"},{"public_id":"co_856964e8560e10f6168effd15f6081f3","name":"hazard ratio","description":"A relative risk measure estimated with Cox proportional hazards regression.","types":["statistical measure","effect estimate"],"url":"https://sah.borca.ai/concepts/co_856964e8560e10f6168effd15f6081f3"},{"public_id":"co_ee0d2eefe709f8b3b0f346e9cf24d220","name":"pravastatin use","description":"Exposure to the statin pravastatin during the follow-up period.","types":["drug exposure","intervention"],"url":"https://sah.borca.ai/concepts/co_ee0d2eefe709f8b3b0f346e9cf24d220"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_c0cbba752a00713606631f7c27497675"}